Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats

In Vivo

Volumn 22, Issue 3, 2008, Pages 391-396

  Shin, Sang Chul ^a   Piao, Yong Ji ^b   Choi, Jun Shik ^b  

^a Chonnam National University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

4 hydroxytamoxifen; Bioavailability; Morin; Pharmacokinetics; Rats; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; MORIN; TAMOXIFEN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FIRST PASS EFFECT; INTESTINE; LIVER METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 45949106460     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jaiyesimi Lk, Buzdar AU, Decker DA and Hortobagyi GN: Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13: 513-529, 1995.
2. Buckley MT and Goa KL: Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Clin Pharmacokin 37: 451-490, 1989.
3. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A and Kupfer D: Metabolism of the antimammary cancer antiestrogenic agent tamoxifen, I. Cytochrome P450-catalysed N-demethylation and 4-hydroxylation. Drug Metab Dispos 21: 645-656, 1993.
4. Crewe HY., Ellis SW, Lennard MS and Tucker GT: Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53: 171-178, 1997.
5. Borgna JL and Rochefort H: Hydroxylated metabolites of tarnoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem 256: 859-868, 1981.
6. Coezy E, Borgna JL and Rochefort H: Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42: 317-323, 1982.
7. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z and Flockhart DA: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758-1764, 2003.
8. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA and Skaar TC: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85: 151-159, 2004.
9. Rao US, Fine RL and Scarborough GA: Antiestrogens, and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 48: 287-292, 1994.
10. Gant TW, O'Connor CK, Corbitt R, Thorgeirsson U and Thorgeirsson SS: In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 133: 269-276, 1995.
11. Sutherland I, Ebner T and Burchell B: The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 45: 295-301, 1993.
12. Turgeon D, Carrier JS, Levesque E, Hum DW and Belanger A: Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142: 778-781, 2001.
13. Wacher VJ, Wu CY and Benet LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129-134, 1995.
14. Hanasaki Y, Ogawa S and Fukui S: The correlation between active oxygen scavenging and antioxidative effects of flavonoids. Free Radic Biol Med 16: 845-850, 1994.
15. Ramanathan L, Das NP and Li QT: Studies on lipid oxidation in fish phospholipid liposomes. Biol Trace Elem Res 40: 59-70, 1994.
16. Kok LD, Wong YP, Wu TW, Chan HC, Kwok TT and Fung KP: Morin hydrate: a potential antioxidant in minimizing the free-radicals-mediated damage to cardiovascular cells by anti-tumor drugs. Life Sci 67: 91-99, 2000.
17. Bhattacharya RK and Firozi PF: Effect of plant flavonoids on microsome catalyzed reactions of aflatoxin B1 leading to activation and DNA adduct formation. Cancer Lett 39: 85-91, 1988.
18. Francis AR, Shetty TK and Bhattacharya RK: Modulating effect of plant flavonoids on the mutagenicity of N-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis 10: 1953-1955, 1989.
19. Kim HK, Cheon BS, Kim YH, Kim SY and Kim HP: Effects of naturally occurring flavonoids on nitric oxide production in the macrophage cell line RAW 264.7 and their structure activity relationships. Biochem Pharmacol 58: 759-765, 1999.
20. Raso GM, Meli R, Di Carlo G, Pacilio M and Di Carlo R: Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci 68: 921-931, 2001.
21. Fang SH, Hou YC, Chang WC, Hsiu SL, Chao PD and Chiang BL: Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock. Life Sci 74: 743-756, 2003.
22. Zhang S and Morris ME: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304: 1258-1267, 2003.
23. Vaclavikova R, Horsky S, Simek P and Gut I: Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioiddants. Naunyn Schiniedebergs Arch Pharmacol 368: 200-209, 2003.
24. Buening MK, Chang RL, Huang MT, Fortner JG, Wood AW and Conney AH: Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 41: 67-72, 1981.
25. Fried KM and Wainer IW: Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J Chromatogr B Biomed Appl 655: 261-268, 1994.
26. Jacolot F, Simon I, Dreano I, Beaune P, Riche C and Berthou F: Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsornes. Biochem Pharmacol 41: 1911-1919, 1991.
27. Hou YC, Chao PD, Ho HJ, Wen CC and Hsiu SL: Profound difference in pharmacokinetics between morin and its isomer quercetin in rats. J Pharm Pharmacol 55: 199-203, 2003.
28. Hsiu SL, Tsao CW, Tsai YC, Ho HJ and Chao PD: Determinations of morin, quercetin and their conjugate metabolites in serum. Biol Pharm Bull 24: 967-969, 2001.
29. Choi JS and Han HK: Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol Res 52: 386-391, 2005.
30. Choi BC, Choi JS and Han HK: Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int J Pharin 323: 81-85, 2006.
31. Shin SC, Choi JS and Li X: Enhanced bioavailability of tamoidfen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 313: 144-149, 2006.